High interleukin-10 (IL-10) levels signal that your immune system is actively trying to dial down inflammation. IL-10 is one of the body’s most powerful anti-inflammatory molecules, and in healthy adults, serum levels typically range from about 5 to 10 pg/mL. When levels climb above that range, it usually means something is driving a strong immune response that the body is trying to counterbalance. What that “something” is varies widely, from infections and autoimmune conditions to certain cancers and critical illness.
What IL-10 Actually Does
IL-10 functions as an immune brake. Nearly every type of immune cell can produce it, including white blood cells called macrophages, T cells, B cells, and even some non-immune cells like the epithelial cells lining your gut. When IL-10 is released, it locks onto receptors on nearby immune cells and triggers a signaling chain that ultimately tells those cells to stop producing inflammatory molecules. The net effect is a cooldown: less tissue damage, less swelling, and a more controlled immune response.
This makes IL-10 essential for preventing your immune system from overshooting. Without it, even a routine infection could spiral into widespread inflammation. But the same braking power that protects healthy tissue can become a problem when it suppresses immunity at the wrong time or in the wrong place.
Chronic Infections and Immune Exhaustion
One of the most well-studied consequences of high IL-10 is its role in allowing chronic infections to persist. In viral infections like HIV, hepatitis B, and hepatitis C, the virus essentially benefits from IL-10’s immunosuppressive effects. Elevated IL-10 produced by immune cells during these infections gradually wears down the very T cells responsible for clearing the virus. These T cells lose the ability to produce the chemical signals they need to fight infection, becoming what researchers call “exhausted.”
In animal studies, persistent viral infection led to a significant increase in IL-10 from antigen-presenting cells (the immune cells that alert T cells to threats). By day 9 of infection, both helper and killer T cells had lost their ability to mount an effective antiviral response. Critically, when IL-10 activity was blocked in lab samples from HIV- and hepatitis C-infected patients, previously unresponsive T cells regained function. This finding underscores that high IL-10 isn’t just a bystander marker of chronic infection; it actively contributes to the immune system’s inability to clear the virus.
Autoimmune Disease: The Lupus Paradox
In autoimmune conditions, particularly systemic lupus erythematosus (SLE), high IL-10 plays a contradictory role. On one hand, it suppresses inflammatory damage to tissues, which should be helpful. On the other hand, IL-10 drives a specific type of antibody production that fuels the disease itself.
In lupus, IL-10 promotes the rapid conversion of activated B cells into antibody-producing cells outside their normal maturation sites in lymph nodes. These fast-tracked cells churn out autoantibodies, the misguided proteins that attack the body’s own tissues. A specialized group of helper T cells found in the blood, lymph nodes, and even kidney tissue of lupus patients supports this process almost entirely through IL-10. So while IL-10 is dampening some inflammation, it’s simultaneously feeding the autoantibody cycle that causes organ damage.
This dual nature makes IL-10 tricky to target therapeutically in lupus. In mouse models, blocking IL-10 early (before disease onset) delayed autoantibody production and symptoms like kidney inflammation. But blocking it after the disease was already established actually worsened autoantibody levels and disease progression.
High IL-10 in Cancer
Tumors can hijack IL-10 to shield themselves from immune attack. Some cancer cells produce IL-10 directly, creating a local environment where immune cells are suppressed and unable to recognize or destroy the tumor. This has been documented across several cancer types, but the data on lung adenocarcinoma is particularly striking.
In patients with lung adenocarcinoma, those whose tumors had high IL-10 levels faced roughly double the risk of death compared to those with low IL-10 levels. Lab experiments confirmed the connection: when researchers knocked down IL-10 production in lung cancer cells, the number of tumor nodules in animal models dropped from an average of 26.5 to 10.5. Conversely, boosting IL-10 production made cancer cells more invasive and better at forming new colonies.
High IL-10 has also been found in the blood of adults with Hodgkin lymphoma. In one study, about half of patients had elevated serum IL-10 (above 10 pg/mL), and those elevated levels were linked to more advanced disease stages, anemia, and worse treatment-free survival.
IL-10 in Spinal Fluid and Brain Lymphoma
When IL-10 is measured in cerebrospinal fluid rather than blood, a high level carries a very specific diagnostic signal. In patients being evaluated for brain tumors, CSF IL-10 levels above 5 pg/mL were 12 times more likely to indicate primary central nervous system lymphoma (PCNSL) than other brain tumors. The average CSF IL-10 in PCNSL patients was 58.2 pg/mL, compared to just 1.5 pg/mL in patients with other brain tumors. At a cutoff of 8.3 pg/mL, the test was 98% specific for PCNSL, meaning a positive result almost certainly pointed to that diagnosis. IL-10 levels also tracked with treatment response, dropping after therapy and rising again if the lymphoma recurred.
Critical Illness and Sepsis
In hospitalized patients with severe infections or sepsis, a surge in IL-10 reflects what’s known as a compensatory anti-inflammatory response. After the initial inflammatory storm, the body overcorrects by flooding the system with anti-inflammatory signals, primarily IL-10. While this prevents ongoing inflammatory tissue damage, it can leave patients dangerously immunosuppressed and vulnerable to secondary infections.
In pediatric ICU patients, high IL-10 levels correlated with dysfunction in three or more organ systems and increased mortality. The ratio of IL-10 to other inflammatory markers also matters: in a study of over 400 patients hospitalized with fever, a higher IL-10-to-TNF ratio predicted death more reliably than either marker alone. During the COVID-19 pandemic, a similar approach proved useful. Tracking changes in the IL-6-to-IL-10 ratio over four days outperformed IL-6 alone in predicting whether hospitalized COVID patients would improve, stay the same, or deteriorate. Each one-point increase in a scoring system based on this ratio was associated with 5.6 times greater odds of a worse outcome.
How IL-10 Is Tested
IL-10 is measured through a blood draw, typically as part of a broader cytokine panel. There are no special fasting requirements or time-of-day restrictions. However, the sample handling is demanding: blood must be placed on ice immediately after collection, spun down within two hours at a cold temperature, and the separated plasma frozen right away. The sample also can’t be shared with other tests or added onto a tube collected earlier. These strict requirements exist because cytokines degrade quickly at room temperature, and delays can produce inaccurate results.
IL-10 is not part of routine bloodwork. It’s typically ordered when a clinician suspects a specific condition, such as an unexplained chronic infection, a possible lymphoma, or monitoring of immune function in critically ill patients. A single elevated reading is rarely diagnostic on its own. Clinicians interpret IL-10 levels alongside other cytokines, imaging, biopsies, and clinical symptoms to build a complete picture.
IL-10 as a Treatment Target
The complex, sometimes contradictory roles of IL-10 have made it an active area of drug development. In cancer, the goal is counterintuitive: rather than blocking IL-10, some therapies aim to deliver it directly to tumors, where at high enough concentrations it can actually rev up killer T cells instead of suppressing them. An early drug candidate called AM0010 showed promising response rates when combined with immune checkpoint inhibitors (41% response rate in metastatic kidney cancer, 43% in non-small cell lung cancer in a phase 1b trial of 111 patients). However, side effects like severe anemia and low platelet counts limited the dose that patients could tolerate, and later-phase trials failed to show a survival benefit.
Newer approaches try to solve this problem by attaching IL-10 to antibodies that deliver it specifically to the tumor, reducing its effects on the rest of the body. Engineered immune cells that secrete IL-10 locally within tumors have shown the ability to overcome T cell exhaustion and generate lasting immune memory in animal models. At least one fusion protein combining IL-10 with a checkpoint inhibitor has entered clinical trials and begun enrolling patients.